Alterity Therapeutics Limited Stock Nasdaq
Equities
ATHE
US02155X2053
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 USD | -2.15% | +6.54% | -8.43% |
Apr. 16 | ADRs End Lower, Purple Biotech Ltd. Declines 29% | DJ |
Apr. 12 | ADRs End Lower, Leju Holdings Ltd. Declines 72% | DJ |
Financials (USD)
Sales 2024 * | 1.87M | Sales 2025 * | 1.39M | Capitalization | 20.39M |
---|---|---|---|---|---|
Net income 2024 * | -8M | Net income 2025 * | -10M | EV / Sales 2024 * | 10.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.7 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.93% |
Latest transcript on Alterity Therapeutics Limited
1 day | -2.15% | ||
1 week | +6.54% | ||
Current month | +10.14% | ||
1 month | +33.33% | ||
3 months | +13.45% | ||
6 months | -8.43% | ||
Current year | -8.43% |
Managers | Title | Age | Since |
---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 63 | 17-04-30 |
Geoffrey Kempler
FOU | Founder | 69 | 97-11-10 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Geoffrey Kempler
FOU | Founder | 69 | 97-11-10 |
Peter Marks
BRD | Director/Board Member | 68 | 05-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 11-08-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.28 | -2.15% | 22 144 |
24-04-24 | 2.33 | +9.39% | 173,935 |
24-04-23 | 2.13 | 0.00% | 33,202 |
24-04-22 | 2.13 | +4.41% | 43,741 |
24-04-19 | 2.04 | -4.67% | 54,226 |
Delayed Quote Nasdaq, April 25, 2024 at 03:31 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.43% | 43.84B | |
+6.90% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+7.49% | 25.53B | |
-24.46% | 18.18B | |
-3.18% | 12.29B | |
+27.79% | 12.29B | |
+7.72% | 11.15B |
- Stock Market
- Equities
- ATH Stock
- ATHE Stock